Clinical Trials Logo
  1. Home
  2. Oral Squamous Cell Carcinoma
  3. NCT05708209
  4. Details
NCT05708209 Clinical Trial

The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124

Oral Squamous Cell Carcinoma Clinical Trial

Official title:
The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05708209
Other study ID # 19038219038211012
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2022
Est. completion date January 1, 2023

Study information
Verified date September 2023
Source Fayoum University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objective: is to determine the diagnostic accuracy of lncRNA MALAT1 as a potential salivary biomarker of OSCC as well as assessment of the salivary expression level of miRNA 124 which is targeted by MALAT1. Materials and Methods: Saliva Samples were collected for the quantitative determination of salivary "MALAT1 and mi RNA -124" using quantitative Real-time Polymerase Chain Reaction technique for the two study groups, Group A: 20 patients with a diagnosis suggestive of OSCC and Group B: 20 age-and-sex-matched healthy individuals, as normal controls.

Description:

Materials and Methods: Saliva Samples were collected for the quantitative determination of salivary "MALAT1 and mi RNA -124" using quantitative Real-time Polymerase Chain Reaction technique for the two study groups, Group A: 20 patients with a diagnosis suggestive of OSCC and Group B: 20 age-and-sex-matched healthy individuals, as normal controls.

Recruitment information / eligibility
Status Completed
Enrollment 40
Est. completion date January 1, 2023
Est. primary completion date December 1, 2022
Accepts healthy volunteers
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - The study included patients with OSCC and healthy controls of both sexes. Exclusion Criteria: - Patients having systemic diseases such as; liver diseases, cardiovascular disease, nervous system, pulmonary, renal, endocrine, gastrointestinal disorders, or other types of cancer were excluded.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Egypt Rania Hassan Shalby Giza

Sponsors (1)
Lead Sponsor Collaborator
Fayoum University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary quantitative determination of salivary non-coding RNAs "MALAT1 quantitative determination of salivary non-coding RNAs "MALAT1 using quantitative Real-time Polymerase Chain Reaction technique (qRT-PCR) in the whole unstimulated saliva 2 months
Secondary quantitative determination of salivary mi RNA -124" quantitative determination of salivary mi RNA -124" using quantitative Real-time Polymerase Chain Reaction technique (qRT-PCR) in the whole unstimulated saliva 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT04543266 - Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
Recruiting NCT05024383 - Dissecting the Heterogeneity of Oral Cancer Pain N/A
Recruiting NCT06031337 - Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
Not yet recruiting NCT06174428 - Validity of Viome's Oral/Throat Cancer Test
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Recruiting NCT05069857 - Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients Phase 2
Not yet recruiting NCT03619304 - Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line N/A
Active, not recruiting NCT01772706 - Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer N/A
Recruiting NCT05893888 - Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05125055 - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Phase 2/Phase 3
Not yet recruiting NCT06055868 - People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Not yet recruiting NCT06130007 - A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. Phase 2
Recruiting NCT05798793 - Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma Phase 3
Recruiting NCT02739204 - Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Phase 2
Recruiting NCT05862168 - Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial Phase 2
Recruiting NCT05451303 - Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
Recruiting NCT05902455 - Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
Not yet recruiting NCT05803915 - Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy Phase 2
Recruiting NCT05791149 - Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity N/A
Active, not recruiting NCT04649476 - Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma Phase 2